Transcriptomic profiling of EBC-1-luc cells treated with HyT compounds and tepotinib
RNA sequencing was performed to characterize transcriptional responses in human EBC-1-luc lung cancer cells following treatment with HyT2, HyT7, or HyT15 at 100 nM, or tepotinib at 15 nM. Vehicle-treated EBC-1-luc cells served as controls. The study includes three biological replicates per condition.